Natalizumab (Solution)
Selected Variant
HY-108831A-01
Size: 5 mg
Natalizumab (Solution) (AN100226; BG00002) is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1) . Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses[1].
Product Specifications
CAS Number
189261-10-7
Product Name Alternative
AN100226; BG00002
UNSPSC
12352203
Target
Integrin
Type
Inhibitory Antibodies
Related Pathways
Cytoskeleton
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/natalizumab-solution.html
Purity
99.0
Solubility
10 mM in DMSO
Smiles
[Natalizumab(Solution)]
Molecular Weight
(146.22 kDa)
References & Citations
[1]Hutchinson M. Natalizumab: A new treatment for relapsing remitting multiple sclerosis. Ther Clin Risk Manag. 2007 Jun;3 (2) :259-68.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 4
Available Sizes
Price
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
HER-2 / c-erbB-2 / neu / CD340 (ERBB2/2453), CF568 conjugate, 0.1mg/mL
TCL1 (T-Cell Marker) (TCL1/2079), CF740 conjugate, 0.1mg/mL
CD3e (T-Cell Marker) (C3e/3125R), CF647 conjugate, 0.1mg/mL
